We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This national competition is designed to support Quebec’s life sciences sector by supporting early-stage companies that align with […]
Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain
Q1 earnings show this Dividend King still looks built for the long term.
In recent weeks, AbbVie reported first-quarter 2026 revenue of US$15,002 million, while also securing new Canadian formulary listings and reimbursement progress for SKYRIZI in ulcerative colitis alongside fresh clinical and regulatory updates for SKYRIZI and RINVOQ across inflammatory and autoimmune diseases. Together with an ongoing dividend record and advances in areas such as immunology, gastroenterology and oncology partnerships, these developments highlight how AbbVie is leaning on its...
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
Clinical Trials Arena rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.
These stocks check off multiple boxes for income investors.
Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.
By holding these top income stocks in your portfolio, you can have a position in some great companies while also generating cash flow each month.
The United States market has remained flat over the last week but is up 28% over the past year, with earnings expected to grow by 16% per annum. In such a climate, identifying undervalued stocks that offer significant discounts can present valuable opportunities for investors seeking growth potential.